Integra LifeSciences (NASDAQ:IART) Stock Price Down 4.1% - What's Next?

Key Points

• Integra LifeSciences' stock price decreased by 4.1%, trading at $14.53, with a significant drop in trading volume.
• Analysts have lowered their price targets for the stock, with a notable cut from Wells Fargo from $25.00 to $13.00, reflecting overall cautious sentiment.
• Despite reporting earnings of $0.45 EPS for the last quarter, Integra's revenue declined by 0.6% year-over-year and the company has set FY 2025 guidance lower at 2.190-2.290 EPS.

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report)'s share price fell 4.1% on Wednesday . The stock traded as low as $14.58 and last traded at $14.53. 128,668 shares were traded during trading, a decline of 88% from the average session volume of 1,038,056 shares. The stock had previously closed at $15.16.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on IART shares. Wells Fargo & Company cut their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. JMP Securities reduced their price target on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Two investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of "Reduce" and an average price target of $18.43.

Integra LifeSciences Stock Performance

The stock has a market capitalization of $1.14 billion, a P/E ratio of -2.24, a PEG ratio of 0.85 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.23 and a quick ratio of 0.73. The stock's 50-day simple moving average is $13.19 and its 200 day simple moving average is $15.90.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The company had revenue of $415.61 million during the quarter, compared to analysts' expectations of $395.06 million. During the same quarter in the previous year, the company posted $0.63 earnings per share. The business's revenue was down .6% on a year-over-year basis. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. Research analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

A number of institutional investors have recently bought and sold shares of IART. Orion Porfolio Solutions LLC boosted its position in shares of Integra LifeSciences by 30.8% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 41,870 shares of the life sciences company's stock valued at $514,000 after purchasing an additional 9,856 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of Integra LifeSciences during the 2nd quarter worth approximately $765,000. State of Wyoming increased its stake in shares of Integra LifeSciences by 84.0% in the 2nd quarter. State of Wyoming now owns 12,953 shares of the life sciences company's stock valued at $159,000 after acquiring an additional 5,914 shares in the last quarter. Public Sector Pension Investment Board lifted its position in shares of Integra LifeSciences by 8.2% during the 2nd quarter. Public Sector Pension Investment Board now owns 227,821 shares of the life sciences company's stock valued at $2,795,000 after acquiring an additional 17,333 shares during the period. Finally, FORA Capital LLC bought a new position in Integra LifeSciences during the second quarter worth $200,000. Institutional investors own 84.78% of the company's stock.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.